An interventional study of AI-assisted antidiabetic drug consultation system and Manual antidiabetic prescribing (without AI) in Type 2 Diabetes Mellitus (T2DM), sponsored by National Taiwan University Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital — 9 open to participants now, 9 under way, none of them phase 3. Diabetes Mellitus, Type 2 · National Taiwan University Hospital.
Among the 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 16th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →9 of the 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 60+
National Taiwan University Hospital · Sites in Taiwan
Ages 20–80
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 92 across the 9 interventional studies, 317 across the 8 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07684690National Taiwan University HospitalAI-Assisted Antidiabetic Drug Consultation System for Glycemic Control in Type 2 Diabetes Patients Managed by Non-Specialist Physicians | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study tests whether an artificial intelligence (AI) tool can help doctors choose better diabetes medicines for their patients. Type 2 diabetes is very common, but there are far more patients than diabetes specialists, so many patients are treated by doctors who are not diabetes specialists. The researchers built an AI consultation system that gives doctors real-time suggestions and predictions about diabetes medicines while they are prescribing. The doctor always makes the final decision.
In this trial, patients with type 2 diabetes whose blood sugar is not well controlled will be placed by chance (randomly) into one of two groups. In one group, the doctor uses the AI system when deciding on diabetes medicines. In the other group, the doctor prescribes as usual, without the AI system. All medicines used are already approved in Taiwan and given at approved doses.
The study follows each patient for 12 months, with check-ups at the start and at 3, 6, 9, and 12 months. The main goal is to compare how much the patients' long-term blood sugar level (HbA1c) improves between the two groups after one year. The researchers also look at how many patients reach their blood sugar target, how often low blood sugar happens, and whether any side effects occur. The aim is to find out whether using the AI tool leads to better blood sugar control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-specialist physicians prescribe antidiabetic medications after consulting the AI-assisted antidiabetic drug consultation system. The system provides real-time, interactive prescribing recommendations, a drug-prioritization order, and outcome predictions. The physician retains full control over the final prescribing decision. All medications are approved in Taiwan and prescribed within approved dose ranges. Patients are followed for 12 months.
Device: AI-assisted antidiabetic drug consultation system
Non-specialist physicians prescribe antidiabetic medications manually according to usual clinical practice, without using the AI consultation system. All medications are approved in Taiwan and prescribed within approved dose ranges. Patients are followed for 12 months.
Other: Manual antidiabetic prescribing (without AI)
A machine-learning based clinical decision support software that provides non-specialist physicians with real-time, interactive antidiabetic prescribing recommendations, a drug-prioritization order, and outcome predictions (e.g., the predicted likelihood of reaching glycemic targets and responder/non-responder status for individual drugs). The system was developed and validated using the NTUH integrated medical database platform. It provides advisory recommendations only; the treating physician retains full control over the final prescribing decision. All recommended medications are approved in Taiwan and within approved dose ranges.
Antidiabetic medications prescribed manually by non-specialist physicians according to usual clinical practice, without using the AI consultation system. All medications are approved in Taiwan and prescribed within approved dose ranges.
Change in HbA1c from baseline to 12 months
The between-group difference in the change in glycated hemoglobin (HbA1c) from baseline to 12 months, comparing the AI-assisted prescribing arm with the manual prescribing (control) arm. HbA1c reflects long-term glycemic control. The primary analysis uses analysis of covariance (ANCOVA) adjusting for baseline HbA1c, following the intention-to-treat principle.
Time frame: Baseline and 12 months
Proportion of participants achieving HbA1c < 7.0% at 12 months
The proportion of participants reaching the glycemic target of HbA1c below 7.0% at 12 months, compared between arms using chi-square tests.
Time frame: 12 months
Incidence of hypoglycemia over 12 months
Incidence of hypoglycemic events over the 12-month follow-up, graded by severity: Level 1, glucose \< 70 mg/dL (3.9 mmol/L) and ≥ 54 mg/dL (3.0 mmol/L); Level 2, glucose \< 54 mg/dL (3.0 mmol/L); Level 3, severe hypoglycemia requiring assistance of another person regardless of glucose value. Compared between arms using Poisson regression.
Time frame: Up to 12 months
Incidence of prespecified adverse events over 12 months
Incidence of prespecified adverse events over the 12-month follow-up, including urinary tract infection, lower-limb edema, signs of heart failure, fractures, nausea, vomiting, and diarrhea. Compared between arms using Poisson regression.
Time frame: Up to 12 months
Change in HbA1c from baseline at 3, 6, 9, and 12 months
Time frame: Baseline, 3, 6, 9, and 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Nov 2027, 16 months later.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 16 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital →